Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2006-12-19
2011-10-25
Li, Bao (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S085100, C530S300000
Reexamination Certificate
active
08043609
ABSTRACT:
The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
REFERENCES:
patent: 5157110 (1992-10-01), Kotwal et al.
patent: 5492135 (1996-02-01), Devore et al.
patent: 5861486 (1999-01-01), Devore et al.
patent: 6129761 (2000-10-01), Hubbell
patent: 6140472 (2000-10-01), Rosengard et al.
patent: 6197934 (2001-03-01), Devore et al.
patent: 6204365 (2001-03-01), Devore et al.
patent: 6331313 (2001-12-01), Wong et al.
patent: 6551595 (2003-04-01), Rosengard et al.
patent: 6692759 (2004-02-01), Wong et al.
patent: 6897290 (2005-05-01), Atkinson et al.
patent: 7084106 (2006-08-01), Kotwal et al.
patent: 7108986 (2006-09-01), Korc et al.
patent: 2002/0102581 (2002-08-01), Hageman et al.
patent: 2003/0017501 (2003-01-01), Hageman et al.
patent: 2003/0207309 (2003-11-01), Hageman et al.
patent: 2006/0263819 (2006-11-01), Hageman et al.
patent: 2007/0238654 (2007-10-01), Deschatelets et al.
patent: 2008/0075755 (2008-03-01), Deschatelets et al.
patent: 0422681 (1991-04-01), None
patent: WO 00/47130 (2000-08-01), None
patent: WO 00/71147 (2000-11-01), None
patent: WO 01/84149 (2001-11-01), None
patent: WO 2004/028635 (2004-04-01), None
patent: WO 2005/023296 (2005-03-01), None
patent: WO 2007/084765 (2007-07-01), None
Song et al. Molecular Biology of the Cell, 2004, vol. 15, pp. 1287-1296.
Acosta, J. et al. “Complement and complement regulatory proteins as potential molecular targets for vascular diseases,” Curr Pharm Des. (2004) 10(2):203-11, Bentham Science Publishers Ltd., Bussum, the Netherlands.
Acosta, J. et al. “Molecular basis for a link between complement and the vascular complications of diabetes,” Proc Nat Acad Sci. (2000) 97 (10): 5450, National Academies of Science, Washington, DC.
Albrecht, J-C. & Fleckenstein, B. “New member of the multigene family of complement control proteins inHerpesvirus saimiri,” J. Virol. (1992) 66: 3937-3940, American Society for Microbiology, Washington, DC.
Albrecht, J. et al. “Herpesvirus saimirihas a gene specifying a homologue of the cellular membrane glycoprotein CD59,” Virology. (1992) 190: 527-530, Academic Press, London, UK.
Ambati, J. et al. “Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies,” Surv. Opthalmol. (2003) 48 (3): 257-293, Elsevier Inc., Amsterdam, The Netherlands.
Bora, P. S. et al. “Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization,” Journal of Immunology (2005) 174(1): 491-497, American Association of Immunologists, Inc., Bethesda, MD.
Francois, C. et al. “Compositions and methods for treatment of macular degeneration and related conditions,” U.S. Appl. No. 11/375,587, filed Mar. 13, 2006. (Not yet published.).
Gerl, V. et al. “Extensive Deposits of Complement C3d and C5b-9 in the Choriocapillaris of Eyes of Patients with Diabetic Retinopathy,” Investigative Ophthalmology and Visual Science (2002) 43 (4): 1104-1108, Association for Research in Vision and Opthalmology, Rockville, MD.
Herold, et al. “Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity,” J. Virol. (1991) 65: 1090-1098, American Society of Microbiology, Washington, DC.
International Preliminary Report on Patentability for PCT/US2005/036547 (Apr. 11, 2007).
International Search Report for PCT/US2005/036547 (Oct. 6, 2006).
Jaffe, G. “Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device,” Invest. Ophthalmol. Vis. Sci. (2000) 41(11): 3569-75, Association for Research in Vision and Opthalmology, Rockville, MD.
Johnson, L et al. “Complement activation and inflammatory processes in drusen formation and age-related macular degeneration,” Experimental Eye Research (2001) 73 (6):887-896, Academic Press, London, United Kingdom.
Kotwal, G. “Poxviral mimicry of complement and chemokine system components: what's the end game?” Immunol. Today (2000) 21(5), 242-248, Elsevier Science Publishers Ltd., London, United Kingdom.
Kotwal, G. et al. “Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins,” Nature (1988) 335: 176-178, Nature Publishing Group, London, United Kingdom.
Makrides, S. “Therapeutic inhibition of the complement system,” Pharm Rev., (1998) 50(1): 59-87, The American Society for Pharmacology and Experimental Therapeutics, Bethesda, MD.
Mettenleiter et al. “Interaction of glycoprotein gIII with a cellular heparinlike substance mediates adsorption of pseudorabies virus,” J. Virol (1990) 64: 278-286, American Society for Microbiology, Washington, DC.
Reid, K. and Day, A. , “Structure-function relationships of the complement components,” Immunol. Today (1989) 10:177-80, Elsevier Science Publishers Ltd., London, United Kingdom.
Rosengard, A. et al. “Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement,” Proc. Natl. Acad. Sci. (2002) 99(13): 8803-8813, National Academy of Sciences, Washington, DC.
Schreuers et al. “Glycoprotein gIII of pseudorabies virus is multifunctional,” J. Virol. (1988) 62: 2251-2257, American Society for Microbiology, Washington, DC.
Smith, S. et al. “Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense,” J. Virol. (2000) 74(12), 5659-5666, American Society for Microbiology, Washington, DC.
Written Opinion for PCT/US2005/036547 (Oct. 6, 2006).
Yamane, K. et al. “Proteome analysis of human vitreous proteins.” Mol Cell Proteomics (2003) 2(11):1177-87, American Society for Biochemistry and Molecular Biology, Inc., Bethesda, MD.
Yannuzzi L. et al. “Retinal angiomatous proliferation in age-related macular degeneration,” Retina (2001) 21 (5):416-34, Lippincott Williams & Wilkins, Hagerstown, MD.
Zhang, J. et al. “Early Complement Activation and Decreased Levels of Glycosylphosphatidylinositol-Anchored Complement Inhibitors in Human and Experimental Diabetic Retinopathy,” Diabetes (2002) 51 (12): 3499-3504, American Diabetes Association, Washington DC.
Liszewski, K.M. et al., “Structure and Regulatory Profile of the Monkeypox Inhibitor of Complement: Comparison to Homologs in Vaccinia and Variola and Evidence for Dimer Formation,” J. Immunol. (2006) 176:3725-3734.
Deschatelets Pascal
Francois Cedric
Olson Paul
Choate Hall & Stewart LLP
Li Bao
Potentia Pharmaceuticals, Inc.
LandOfFree
Viral complement control proteins for eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral complement control proteins for eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral complement control proteins for eye disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271260